Redhill Biopharma Ltd. (NASDAQ:RDHL) Short Interest Update

Redhill Biopharma Ltd. (NASDAQ:RDHL – Get Free Report) was the recipient of a significant decrease in short interest during the month of August. As of August 14th, there was short interest totaling 14,705 shares, a decrease of 50.9% from the July 30th total of 29,926 shares. Currently, 0.3% of the company’s shares are sold short. Based on an average daily volume of 28,818 shares, the days-to-cover ratio is presently 0.5 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Redhill Biopharma in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Redhill Biopharma has an average rating of “Sell”.

Get Redhill Biopharma alerts:

Get Our Latest Analysis on RDHL

Redhill Biopharma Stock Performance

Shares of RDHL traded up $0.03 during trading hours on Friday, hitting $0.66. The stock had a trading volume of 42,431 shares, compared to its average volume of 25,310. Redhill Biopharma has a 12-month low of $0.57 and a 12-month high of $2.79. The firm has a market cap of $4.02 million, a P/E ratio of 0.00 and a beta of 5.00. The company’s fifty day simple moving average is $0.70 and its 200 day simple moving average is $0.84.

Hedge Funds Weigh In On Redhill Biopharma

A hedge fund recently bought a new stake in Redhill Biopharma stock. Yorkville Advisors Global LP purchased a new stake in Redhill Biopharma Ltd. (NASDAQ:RDHL – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 386,593 shares of the biotechnology company’s stock, valued at approximately $398,000. Redhill Biopharma accounts for about 0.3% of Yorkville Advisors Global LP’s holdings, making the stock its 19th largest holding. Yorkville Advisors Global LP owned approximately 7.57% of Redhill Biopharma at the end of the most recent reporting period. Institutional investors own 7.20% of the company’s stock.

About Redhill Biopharma

(Get Free Report)

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.

Featured Stories

• Five stocks we like better than Redhill Biopharma
• From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
• These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
• Venture Into High-Volatility Corners of the Market With These 3 ETFs
• 3 Retail Stocks to Watch After a Big Consumer Earnings Week

Receive News & Ratings for Redhill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.